NTLA

SEC source: 0001209191-17-064786 · doc4.xml · nonDerivative · entry 3

Bermingham Nessan · CIK 0001377759 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 579,959

F3 · price: The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.33 to $21.32. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-17-064786 · doc4.xml · nonDerivative · entry 2

Bermingham Nessan · CIK 0001377759 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 683,533

F2 · price: The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.70 to $21.12. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-17-064786 · doc4.xml · nonDerivative · entry 1

Bermingham Nessan · CIK 0001377759 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 696,000

F1 · price: The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $19.70 to $20.69. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-17-059054 · doc4.xml · nonDerivative · entry 1

Bell Graeme · CIK 0001643757 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,400

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.85 to $22.15.

SEC source: 0001415889-17-001484 · form4-09132017_030948.xml · nonDerivative · entry 1

Caribou Biosciences, Inc. · CIK 0001619856 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,545,000

F1 · price: The transfer of stock relates to the Exclusive License Agreement, by and among Caribou Biosciences, Inc., The Regents of the University of California, and the University of Vienna, dated April 16, 2013.

F2 · ownership.nature: This Form 4 is filed on behalf of (i) Caribou Therapeutics Holdco, LLC, the direct holder of the shares, and (ii) Caribou Biosciences, Inc. Caribou Therapeutics Holdco, LLC is a wholly-owned subsidiary of Caribou Biosciences, Inc., and thus Caribou Biosciences, Inc. may be deemed to share voting and dispositive power with respect to the shares held by Caribou Therapeutics Holdco, LLC. Caribou Biosciences, Inc. disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-17-046188 · doc4.xml · derivative · entry 1

Slaoui Moncef · CIK 0001712369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2027-07-24

F1 · derivative.exercise_date: This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter.

SEC source: 0001209191-17-046194 · doc4.xml · derivative · entry 1

Verwiel Frank · CIK 0001545794 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2027-07-24

F1 · derivative.exercise_date: This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter.

SEC source: 0001104659-17-044530 · a4.xml · nonDerivative · entry 3

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,579,788

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.325, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.

F5 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-17-044529 · a4.xml · nonDerivative · entry 3

Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner

Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner

Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,579,788

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.325, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.

F5 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001104659-17-044530 · a4.xml · nonDerivative · entry 2

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,659,788

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

F5 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-17-044529 · a4.xml · nonDerivative · entry 2

Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner

Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner

Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,659,788

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.70, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

F5 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001104659-17-044530 · a4.xml · nonDerivative · entry 1

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,699,788

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 - $17.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

F5 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001104659-17-044529 · a4.xml · nonDerivative · entry 1

Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner

Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner

Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,699,788

F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 - $17.25, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

F5 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-17-037520 · doc4.xml · nonDerivative · entry 1

DORSA CAROLINE · CIK 0001181174 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001209191-17-037516 · doc4.xml · nonDerivative · entry 1

Bell Graeme · CIK 0001643757 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,400

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.49, inclusive.

SEC source: 0001209191-17-037514 · doc4.xml · nonDerivative · entry 1

Rivera Jose E · CIK 0001671870 · EVP, General Counsel & Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,994

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.98 to $12.04, inclusive.

F2 · balance_after: Includes 594 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2016.

SEC source: 0001209191-17-037518 · doc4.xml · nonDerivative · entry 1

KARSEN PERRY A · CIK 0001260573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001209191-17-037512 · doc4.xml · nonDerivative · entry 2

LEONARD JOHN M. · CIK 0001563584 · Director · EVP, R&D

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 8,400

F1 · ownership.nature: Shares acquired and held by the John Leonard Defined Benefit Pension Plan and Trust.

SEC source: 0001209191-17-037512 · doc4.xml · nonDerivative · entry 1

LEONARD JOHN M. · CIK 0001563584 · Director · EVP, R&D

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 7,800

F1 · ownership.nature: Shares acquired and held by the John Leonard Defined Benefit Pension Plan and Trust.

SEC source: 0001209191-17-037510 · doc4.xml · nonDerivative · entry 1

Bermingham Nessan · CIK 0001377759 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 795,033

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.88 to $12.05, inclusive.

SEC source: 0001209191-17-033985 · doc4.xml · derivative · entry 1

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2027-05-17

F1 · derivative.exercise_date: This option was granted on May 18, 2017 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-17-033988 · doc4.xml · derivative · entry 1

DORSA CAROLINE · CIK 0001181174 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2027-05-17

F1 · derivative.exercise_date: This option was granted on May 18, 2017 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-17-033983 · doc4.xml · derivative · entry 1

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2027-05-17

F1 · derivative.exercise_date: This option was granted on May 18, 2017 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

F2 · ownership.direct: The Reporting Person is a member of OrbiMed Advisors LLC ("Advisors") and is obligated to transfer any shares issued pursuant to any equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors for the ultimate benefit of OrbiMed Private Investments V, LP and OrbiMed Global Healthcare Master Fund, LP. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-033980 · doc4.xml · derivative · entry 1

KARSEN PERRY A · CIK 0001260573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2027-05-17

F1 · derivative.exercise_date: This option was granted on May 18, 2017 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-17-020050 · doc4.xml · nonDerivative · entry 2

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · security: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.86 - $14.33, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

F1 · ownership.nature: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-17-020055 · doc4.xml · nonDerivative · entry 2

Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner

Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP, and disclaims Section 16 beneficial ownership of the securities held by AVA IX LP, except to the extent of its pecuniary interest therein, if any. On March 3, 2017 AVA IX LP received 21,132 shares of the issuer's common stock from Atlas Venture Fund IX, L.P. (the "Fund") in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act").

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.86 - $14.33, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

SEC source: 0001209191-17-020050 · doc4.xml · nonDerivative · entry 1

FORMELA JEAN FRANCOIS · CIK 0001030575 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,504

F1 · security: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 - $14.02, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

F1 · ownership.nature: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-17-020055 · doc4.xml · nonDerivative · entry 1

Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner

Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,504

F1 · security: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP, and disclaims Section 16 beneficial ownership of the securities held by AVA IX LP, except to the extent of its pecuniary interest therein, if any. On March 3, 2017 AVA IX LP received 21,132 shares of the issuer's common stock from Atlas Venture Fund IX, L.P. (the "Fund") in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act").

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 - $14.02, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

SEC source: 0001209191-17-018679 · doc4.xml · nonDerivative · entry 1

Novartis Institutes for BioMedical Research, Inc. · CIK 0001673852 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,652,903

F1 · kind: Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. ("NIBRI") is a limited partner.

F2 · ownership.direct: The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG.

SEC source: 0001209191-17-018547 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner

Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner

Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,729,788

F1 · kind: On March 3, 2017, Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX") distributed, for no consideration, 700,000 shares of the Issuer's Common Stock pro-rata to its partners, including its limited partners and its general partner, Atlas Venture Associates IX, L.P. ("AVA IX LP"), in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act").

F1 · price: On March 3, 2017, Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX") distributed, for no consideration, 700,000 shares of the Issuer's Common Stock pro-rata to its partners, including its limited partners and its general partner, Atlas Venture Associates IX, L.P. ("AVA IX LP"), in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act").

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX. Each of AVA IX LP and Atlas Venture Associates IX, LLC, its general partner ("AVA IX LLC") disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-17-003284 · doc4.xml · derivative · entry 1

Rivera Jose E · CIK 0001671870 · EVP, General Counsel & Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2027-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 115,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001209191-17-003288 · doc4.xml · derivative · entry 1

Barnes Thomas M. · CIK 0001670577 · SVP, R&D eXtellia

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,500

Underlying: Common Stock · 50,500 shares

Expires 2027-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 50,500 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001209191-17-003291 · doc4.xml · derivative · entry 1

Morrissey David V · CIK 0001670998 · SVP, Platform & Delivery Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 30,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001209191-17-003293 · doc4.xml · derivative · entry 1

Heifner Nicole · CIK 0001670999 · SVP, Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2027-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 28,500 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001209191-17-003286 · doc4.xml · derivative · entry 1

LEONARD JOHN M. · CIK 0001563584 · Director · EVP, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2027-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 95,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001209191-17-003282 · doc4.xml · derivative · entry 1

Bermingham Nessan · CIK 0001377759 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Common Stock · 270,000 shares

Expires 2027-01-05

F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 270,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001209191-17-002291 · doc4.xml · derivative · entry 1

Bell Graeme · CIK 0001643757 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2027-01-02

F1 · derivative.exercise_date: This option was granted on January 3, 2017 with respect to 210,000 shares of Common Stock, with 25% vesting on December 12, 2017 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.